A synthetic analogue of growth hormone-releasing hormone (GHRH). Studied for its extended half-life and effects on somatotroph receptor signalling in pituitary cell models.
Add sterile bacteriostatic water to the vial to achieve your target working concentration.
Storage conditions: -20°C, dry
Form: Lyophilised
Solubility: Water, BAC water
Current batch: CND10-260429-055
HPLC purity: 99.63%
MS verified: Yes
Expiry: Apr 2028
The certificate of analysis for this batch is issued with your order.
C₁₅₂H₂₅₂N₄₄O₄₂ · 3,367.9 Da
CJC-1295
out of stock
Free shipping on orders over £75
Working out volumes? Peptide calculator · Reconstitution guide
CND10-260429-055 · HPLC 99.63%
The batch code matches the vial you will receive. Full analysis — purity, mass spectrometry, residual solvents and microbial limits — is issued with your order.
| Content | 2mg |
| Purity | 99.63% HPLC |
| Form | Lyophilised |
| Storage | -20°C, dry |
| Solubility | Water, BAC water |
Same-day dispatch — order within
Same-day dispatch before 3pm, Mon–Fri. Next dispatch .
via Royal Mail Tracked 24
CJC-1295
2mg · £17.99
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone. It is supplied here without DAC — the drug affinity complex that binds the molecule to serum albumin and extends its half-life substantially. The two forms behave differently and the literature reports them separately, so a protocol specifying one is not satisfied by the other.
Teichman and colleagues published on prolonged stimulation of growth hormone and IGF-1 secretion by CJC-1295 in the Journal of Clinical Endocrinology and Metabolism in 2006, with follow-up work on the GH/IGF-1 axis in Growth Hormone and IGF Research.
Mechanism in the literature
As a GHRH analogue, CJC-1295 acts at the growth hormone-releasing hormone receptor on the anterior pituitary. Published work describes downstream effects on the growth hormone and IGF-1 axis.
CJC-1295 holds no marketing authorisation as a medicine in the United Kingdom or the United States. Material supplied here is for laboratory research only.
Handling and reconstitution
Supplied lyophilised at 2mg and 5mg. Room temperature before reconstituting, diluent down the vial wall, gentle swirling.
Storage and stability
Lyophilised at -20°C, protected from light, two-year retest date. Reconstituted solution refrigerated and used within a short window.
Common questions
Is this CJC-1295 with or without DAC?
Without DAC. The drug affinity complex extends half-life considerably by binding the peptide to serum albumin, and the two forms are reported separately in the literature. Check which one a protocol calls for before ordering — they are not interchangeable.
What purity is BSR's CJC-1295?
The current batch tests at 99.63% by HPLC with LC-MS identity confirmation at 3367.4 Da against a theoretical 3367.90. The certificate is issued with your order.
Why is it often listed alongside Ipamorelin?
They act on different receptors — CJC-1295 at the GHRH receptor, Ipamorelin at the ghrelin receptor — and appear together frequently enough in the research literature that suppliers tend to list them as a pair.
- Teichman S.L. et al. (2006) — Prolonged stimulation of GH and IGF-I secretion by CJC-1295, Journal of Clinical Endocrinology and Metabolism
- Sackmann-Sala L. et al. (2009) — Activation of the GH/IGF-1 axis by CJC-1295, Growth Hormone and IGF Research
Cited as research context. BSR has no involvement in these studies and they do not constitute claims about this product.
No reviews of this compound yet. Reviews come only from customers who have bought it.
Sign in to review a compound you have bought.